secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-08-21T21:17:59+00:00
Accession:  0001213900-26-092690
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial receives Nasdaq delisting notice for equity shortfall
-----------------------------------------------------------

- On Aug 18, 2026, Nasdaq said stockholders' equity fell below $2.5M minimum for continued listing.
- Company also fails alternative $35M market value or $500K net income standards.
- Must submit compliance plan by Oct 2, 2026; intends to convert Series A preferred stock at 2026 annual meeting.
- If accepted, Nasdaq may grant up to 180-day extension; delisting stay via hearing possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026092690/0001213900-26-092690-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026092690/ea0302970-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-092690

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer